PainReform

Company Overview

Snapshot

Founded in December 2007, PainReform operates with 1–10 employees and has raised a total of $46.3 million across 5 funding rounds. The company went public on NASDAQ in September 2020, raising $23 million in its IPO.

Business overview

PainReform is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics. The company's core technology involves a proprietary drug-delivery system designed to provide extended post-surgical pain relief, reducing the need for repeated doses and minimizing opiate use. PainReform leverages the FDA's 505(b)(2) regulatory pathway to accelerate development by incorporating generic drugs with proven safety and efficacy into its extended-release products. Its initial product, PRF-110, targets the post-operative pain relief market using the local anesthetic ropivacaine. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drug Delivery, serving patients and healthcare providers in markets such as North America, Europe, and Asia.

Strategic signal

In May 2026, PRF Technologies, an entity associated with PainReform, announced that its PRF-110 product demonstrated sustained 72-hour analgesic activity comparable to an approved, commercially available benchmark in a head-to-head preclinical study. This preclinical validation of PRF-110's extended pain relief capabilities signals potential for the company's lead candidate in the post-operative pain management market and could enhance its competitive positioning against existing treatments.

Company Intelligence Q&A

What was a significant recent development for PainReform's PRF-110 product?

In May 2026, PRF Technologies announced that PRF-110 demonstrated sustained 72-hour analgesic activity comparable to an approved, commercially available benchmark in a head-to-head preclinical study.

What was a key strategic move by PainReform in March 2025?

In March 2025, PainReform completed the strategic acquisition of DeepSolar, aiming to unlock new growth opportunities in AI-driven solar analytics.

What was the outcome of PainReform's public offering in April 2024?

In April 2024, PainReform announced the pricing of a $4 million public offering.

What was a notable event regarding PainReform's PRF-110 clinical trial in September 2023?

In September 2023, PainReform announced plans to commence the second part of its Phase 3 clinical trial to evaluate PRF-110 in patients undergoing bunionectomy surgery, following a positive FDA review of its Drug Master File.

When did PainReform go public and how much capital was raised?

In September 2020, PainReform went public on NASDAQ, raising $23 million in its Initial Public Offering with a valuation of $70 million.